Well, we've seen what happens if no Canadian companies are working in this area. We saw that during COVID-19. We end up being not on the leading edge of new discoveries and not being on the receiving end of new discoveries either.
We're seeing this now in the pharmaceutical industry in antibiotics, for example. Those are the risks that we face. We face a lack of access to new drugs if we don't help build this area.